Rebecca Fisher, M.D.

Provider Type: Physician

Specialties:

Board Certifications:

Texas Oncology-Austin Brain Tumor Center
901 W. 38th St., Suite 200
Austin, TX 78705
T: 512-421-4100
contact_phone Download Contact Card

Metro Area: Austin

Spoken Language: English

Fellowship in Neuro-Oncology
Memorial Sloan Kettering Cancer Center, New York, NY
Residency in Neurology, Chief Resident
University of Massachusetts Medical School, Worcester, MA
Internship in Internal Medicine
Saint Vincent Hospital, Worcester, MA
Medical Doctorate
The Warren Alpert Medical School of Brown University, Providence, RI and Geisel School of Medicine at Dartmouth, Hanover, NH

Adjuvant Therapy for Patients with Newly Diagnosed Glioblastoma Multiforme
Nova Science Publishers, 2015
Management of Isolated Leptomeningeal Metastasis: Initial and Sole Site of Recurrence in a Patient with Early-stage Breast Cancer
International Cancer Conference Journal, 2015
Therapeutic Plasma Exchange in a Patient with Paraneoplastic variant Stiff Person Syndrome
American Association of Blood Banks, 2014 Annual Meeting, 2014
Radiation Exposure as a Link to Primary Ocular Diffuse Large B-cell Lymphoma
American Society of Clinical Oncology (ASCO), 2014 Annual Meeting, 2014
Route of Intra-cerebrospinal Fluid Chemotherapy Administration and Efficacy of Therapy in Neoplastic Meningitis
Cancer, 2010

Leptomeningeal Metastases in Breast Cancer
Diseases of the Breast, 2008
Phase II Trial of High-Dose Intravenous Methotrexate, Rituxan, and Intra-CSF DepoCyt in Patients with Newly Diagnosed Primary CNS Lymphoma
Journal of Neuro-Oncology, 2007
Interaction between Route of Intra-CSF Chemotherapy Administration and Efficacy of Therapy in Patients with Neoplastic Meningitis
Neurology, 2006
Potential Efficacy of Somatostatin for Treatment of Recurrent Meningiomas
Neurology, 2006

Stem Cell Radiotherapy and temozolomide for Newly Diagnosed High Grade Glioma; prospective phase I/II trial co-investigator (IRB approved, NCT02039778)
Concurrent Bevacizumab and re-irradiation versus Bevacizumab alone as treatment for recurrent glioblastoma; randomized phase II trial co-investigator (RTOG 1205, NCT01730950)
Cabozantinib in Combination with Temozolomide and Radiation Therapy in the Initial Treatment of Adults with Glioblastoma; phase I trial co-investigator (IRB approved, NCT00960492)
Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects with Grade IV Astrocytic Tumors in First or Second Relapse; phase II trial co-investigator (IRB approved, NCT01068782)